Provexis (PXS.L) Stock Price

Provexis Price

Delisted
0.01GBP
Last traded price
Today +/-
Today %

Provexis (PXS.L) Stock | ISIN GB00B0923P27 | WKN A0ETZW. The current Provexis stock price is 0.01 GBP (2026). Market capitalization is 23.48 M GBP. Provexis operates in the Non-cyclical consumption sector.

Revenue has compounded at 8.6% per year over the past 19 years to 1.29 M GBP. Provexis's net margin stands at -35%, up from -67.5% several years earlier.

Provexis stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Provexis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Provexis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Provexis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Provexis Stock Price History
DateProvexis Price
Access this data via the Eulerpool API

Provexis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
270,000 GBP
-3.37 M GBP
-3.41 M GBP
Jan 1, 2007
810,000 GBP
-2.87 M GBP
-2.92 M GBP
Jan 1, 2008
160,000 GBP
-1.21 M GBP
-1.19 M GBP
Jan 1, 2009
10,000 GBP
-1.58 M GBP
-4.57 M GBP
Jan 1, 2010
10,000 GBP
-1.79 M GBP
-1.65 M GBP
Jan 1, 2011
50,000 GBP
-2.48 M GBP
-1.98 M GBP
Jan 1, 2012
3.48 M GBP
-4.33 M GBP
-3.87 M GBP
Jan 1, 2013
5.56 M GBP
-4.35 M GBP
-4.34 M GBP
Jan 1, 2014
0 GBP
-970,000 GBP
490,000 GBP
Jan 1, 2015
38,200 GBP
-498,200 GBP
-435,600 GBP
Jan 1, 2016
91,700 GBP
-455,500 GBP
-409,600 GBP
Jan 1, 2017
227,600 GBP
-412,000 GBP
-380,100 GBP
Jan 1, 2018
235,800 GBP
-467,900 GBP
-448,100 GBP
Jan 1, 2019
322,200 GBP
-533,900 GBP
-513,000 GBP
Jan 1, 2020
347,900 GBP
-424,800 GBP
-406,200 GBP

Provexis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 19, 2026, 12:25 PM
 
REVENUE (M GBP)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M GBP)
NET INCOME (M GBP)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
20182019202020212022202320242025
00000001
300
33333333
00000000
1.851.932.012.12.212.222.222.28
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Provexis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Provexis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Provexis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Provexis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Provexis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Provexis stock margins

The Provexis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Provexis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Provexis.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
33.33 %
-1,248.15 %
-1,262.96 %
Jan 1, 2007
49.38 %
-354.32 %
-360.49 %
Jan 1, 2008
41.24 %
-756.25 %
-743.75 %
Jan 1, 2009
41.24 %
-15,800 %
-45,700 %
Jan 1, 2010
41.24 %
-17,900 %
-16,500 %
Jan 1, 2011
100 %
-4,960 %
-3,960 %
Jan 1, 2012
50.57 %
-124.43 %
-111.21 %
Jan 1, 2013
56.47 %
-78.24 %
-78.06 %
Jan 1, 2014
41.24 %
- %
- %
Jan 1, 2015
41.24 %
-1,304.19 %
-1,140.31 %
Jan 1, 2016
41.24 %
-496.73 %
-446.67 %
Jan 1, 2017
95.83 %
-181.02 %
-167 %
Jan 1, 2018
90.16 %
-198.43 %
-190.03 %
Jan 1, 2019
84.67 %
-165.7 %
-159.22 %
Jan 1, 2020
89.74 %
-122.1 %
-116.76 %

Provexis Stock Revenue, EBIT, Earnings per Share

The Provexis earnings per share therefore indicates how much revenue Provexis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0 GBP
-0.02 GBP
-0.02 GBP
Jan 1, 2007
0 GBP
-0.01 GBP
-0.01 GBP
Jan 1, 2008
0 GBP
-0 GBP
-0 GBP
Jan 1, 2009
0 GBP
-0 GBP
-0.01 GBP
Jan 1, 2010
0 GBP
-0 GBP
-0 GBP
Jan 1, 2011
0 GBP
-0 GBP
-0 GBP
Jan 1, 2012
0 GBP
-0 GBP
-0 GBP
Jan 1, 2013
0 GBP
-0 GBP
-0 GBP
Jan 1, 2014
0 GBP
-0 GBP
0 GBP
Jan 1, 2015
0 GBP
-0 GBP
-0 GBP
Jan 1, 2016
0 GBP
-0 GBP
-0 GBP
Jan 1, 2017
0 GBP
-0 GBP
-0 GBP
Jan 1, 2018
0 GBP
-0 GBP
-0 GBP
Jan 1, 2019
0 GBP
-0 GBP
-0 GBP
Jan 1, 2020
0 GBP
-0 GBP
-0 GBP

Provexis business model & stock analysis

Provexis PLC is a British company in the food and health industry that specializes in the development of functional food and sports supplementation products. The company was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis SWOT Analysis

Strengths

Provexis PLC has several strengths that contribute to its competitive advantage in the market. These include:

  • Strong product portfolio: Provexis PLC offers a range of innovative and high-quality products in the healthcare industry.
  • Technological expertise: The company has a strong track record of developing and utilizing cutting-edge technologies to enhance its products and services.
  • Established brand and reputation: Provexis PLC has built a strong brand image and reputation through its commitment to excellence and customer satisfaction.
  • Strategic partnerships: The company has successfully formed strategic alliances with key stakeholders and industry leaders to expand its market reach.

Weaknesses

Despite its strengths, Provexis PLC also has some weaknesses that may hinder its growth and success. These weaknesses include:

  • Limited market presence: The company's products may have limited market penetration, making it challenging to compete with larger and more established players.
  • Dependency on key customers: Provexis PLC relies heavily on a few major customers, which poses a risk if these customers reduce their purchases or switch to competitors.
  • Financial constraints: The company may face financial constraints in terms of funding research and development efforts or expanding its operations.

Opportunities

Provexis PLC can leverage various opportunities in the market to drive growth and profitability. These opportunities include:

  • Growing healthcare industry: The increasing demand for healthcare products and services presents avenues for Provexis PLC to expand its market share.
  • Emerging markets: The company can explore untapped markets and expand its global presence, particularly in emerging economies with rising disposable incomes.
  • Product diversification: Provexis PLC can explore diversifying its product offerings to cater to a wider range of customer needs and preferences.

Threats

Provexis PLC faces certain threats that may pose challenges to its operations and profitability. These threats include:

  • Intense competition: The healthcare industry is highly competitive, with many players offering similar products and services.
  • Regulatory challenges: Compliance with regulatory standards and obtaining necessary approvals can be time-consuming and costly for Provexis PLC.
  • Market volatility: Fluctuations in market conditions and economic uncertainties may impact the demand for Provexis PLC's products.

Provexis Eulerpool Fair Value

Provexis historical P/E ratio, EBIT multiple, and P/S ratio

Provexis annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Provexis shares outstanding

The number of shares was Provexis in 2025 — This indicates how many shares 2.284 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
212.79 M base_Shares
Jan 1, 2007
266.42 M base_Shares
Jan 1, 2008
420.07 M base_Shares
Jan 1, 2009
647.24 M base_Shares
Jan 1, 2010
940.61 M base_Shares
Jan 1, 2011
1.16 B base_Shares
Jan 1, 2012
1.4 B base_Shares
Jan 1, 2013
1.5 B base_Shares
Jan 1, 2014
1.54 B base_Shares
Jan 1, 2015
1.57 B base_Shares
Jan 1, 2016
1.63 B base_Shares
Jan 1, 2017
1.71 B base_Shares
Jan 1, 2018
1.85 B base_Shares
Jan 1, 2019
1.93 B base_Shares
Jan 1, 2020
2.01 B base_Shares
Price targets and forecasts for Provexis are not yet available.

Provexis shareholder structure

% Name
11.23912%
DSM Venturing B.V.
DSM Venturing B.V.
9.56517%
Lucas (Stuart)
Lucas (Stuart)
1.61605%
Milligan (James)
Milligan (James)
1.51391%
Lucas (Kiman)
Lucas (Kiman)
1.18559%
Buck (Charles Dawson)
Buck (Charles Dawson)
1.08556%
Wyatt (Gary Charles)
Wyatt (Gary Charles)
0.52896%
Lucas (Sean)
Lucas (Sean)
0.52896%
Lucas (Megan I)
Lucas (Megan I)
0.52896%
Botha (Ruth)
Botha (Ruth)
0.43776%
Ford (Ian)
Ford (Ian)

Provexis Executives and Management Board

IF

Mr. Ian Ford

Chief Executive Officer, Executive Director, Secretary · since 2007

Compensation168,749 GBP
NO

Dr. Niamh O'Kennedy

Chief Scientific Officer, Executive Director

Compensation94,109 GBP
CB

Mr. C. Dawson Buck

Non-Executive Chairman of the Board

Compensation27,600 GBP

Provexis Supply Chain

Frequently asked questions about Provexis

The business model of Provexis PLC revolves around developing and commercializing scientifically supported products. Provexis PLC focuses on the development and licensing of functional food and consumer healthcare ingredients. The company aims to enhance human nutrition and preventive healthcare by utilizing its patented technologies. Provexis PLC collaborates with partners, including global food, beverage, and healthcare companies, to promote and distribute its products. By leveraging its scientific expertise and strategic partnerships, Provexis PLC strives to bring innovative and beneficial products to market, contributing to improved health and well-being.

All fundamentals and in-depth analysis of Provexis

Our stock analysis for Provexis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provexis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.